The mTOR pathway is frequently activated in pancreatic ductal adenocarcinoma and chronic pancreatitis

Applied Immunohistochemistry and Molecular Morphology

Volumn 18, Issue 5, 2010, Pages 442-447

  Bellizzi, Andrew M ^a   Bloomston, Mark ^a   Zhou, Xiao Ping ^a   Iwenofu, Obiajulu Hans ^a   Frankel, Wendy L ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Akt; chronic pancreatitis; ductal adenocarcinoma; immunohistochemistry; mTOR; oncoprotein; pancreas; PTEN; rapamycin; RPS6; tumor suppressor

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN S6;

ARTICLE; CASE FINDING; CHRONIC PANCREATITIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATION; MAJOR CLINICAL STUDY; ONCOGENESIS AND MALIGNANT TRANSFORMATION; PANCREAS; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; TISSUE MICROARRAY;

CARCINOMA, DUCTAL; HUMANS; IMMUNOHISTOCHEMISTRY; PANCREAS; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; PTEN PHOSPHOHYDROLASE; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 77957585606     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181de115b     Document Type: Article

References (52)

1. Hruban RH, Pitman MB, Klimstra DS Ductal Adenocarcinoma. AFIP Atlas of Tumor Pathology: Tumors of the Pancreas. Vol. 6. Washington, DC: American Registry of Pathology; 2007: 111-164.
2. Kloppel G, Hruban RH, Longnecker D.S., et al. Ductal adenocarci-noma of the pancreas. In: Hamilton SR, Aaltonen LA, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System, Vol. Lyon: IARC Press; 2000: 221-230.
3. Katz MH, Wang H, Fleming J.B., et al. Long-term survival after multidisciplinary management of resected pancreatic adenocar-cinoma. Ann Surg Oncol. 2009; 16: 836-847.
4. Nieto J, Grossbard ML, Kozuch P. Metastatic pancreatic cancer 2008: is the glass less empty? Oncologist. 2008; 13: 562-576.
5. Wolff RA. Exploiting molecular targets in pancreatic cancer. Hematol Oncol Clin North Am. 2002; 16: 139-157.
6. Xiong HQ. Molecular targeting therapy for pancreatic cancer. Cancer Chemother Pharmacol. 2004; 54(SUPPL. 1): S69-S77.
7. Corradetti MN, Guan KL Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene. 2006; 25: 6347-6360.
8. LoPiccolo J, Blumenthal GM, Bernstein W.B., et al. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat. 2008; 11: 32-50.
9. Gera JF, Mellinghoff IK, Shi Y, et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem. 2004; 279: 2737-2746.
10. Grolleau A, Bowman J, Pradet-Balade B, et al. Global and specific translational control by rapamycin in T cells uncovered by microarrays and proteomics. J Biol Chem. 2002; 277: 22175-22184.
11. Dufner A, Andjelkovic M, Burgering B.M., et al. Protein kinase B localization and activation differentially affect S6 kinase 1 activity and eukaryotic translation initiation factor 4E-binding protein 1 phosphorylation. Mol Cell Biol. 1999; 19: 4525-4534.
12. Ferrari S, Bandi HR, Hofsteenge J, et al. Mitogen-activated 70K S6 kinase. Identification of in vitro 40S ribosomal S6 phosphorylation sites. J Biol Chem. 1991; 266: 22770-22775.
13. Nojima H, Tokunaga C, Eguchi S., et al. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem. 2003; 278: 15461-15464.
14. Sekulic A, Hudson CC, Homme J.L., et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 2000; 60: 3504-3513.
15. Scott PH, Brunn GJ, Kohn A.D., et al. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc Natl Acad Sci U S A. 1998; 95: 7772-7777.
16. Sun H, Lesche R, Li D.M., et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A. 1999; 96: 6199-6204.
17. Cheng JQ, Ruggeri B, Klein W.M., et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A. 1996; 93: 3636-3641.
18. Miwa W, Yasuda J, Murakami Y., et al. Isolation of DNA sequences amplified at chromosome 19q13.1-q13.2 including the AKT2 locus in human pancreatic cancer. Biochem Biophys Res Commun. 1996; 225: 968-974.
19. Ruggeri BA, Huang L, Wood M., et al. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog. 1998; 21: 81-86.
20. Schlieman MG, Fahy BN, Ramsamooj R, et al. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer. 2003; 89: 2110-2115.
21. Grewe M, Gansauge F, Schmid R.M., et al. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res. 1999; 59: 3581-3587.
22. Perugini RA, McDade TP, Vittimberga FJ Jr, et al. Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent. J Surg Res. 2000; 90: 39-44.
23. Altomare DA, Tanno S, De Rienzo A, et al. Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem. 2002; 87: 470-476.
24. Bondar VM, Sweeney-Gotsch B, Andreeff M., et al. Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther. 2002; 1: 989-997.
25. Asano T, Yao Y, Zhu J., et al. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene. 2004; 23: 8571-8580.
26. Asano T, Yao Y, Zhu J., et al. The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. Biochem Biophys Res Commun. 2005; 331: 295-302.
27. Ito D, Fujimoto K, Mori T., et al. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int J Cancer. 2006; 118: 2337-2343.
28. Pham NA, Schwock J, Iakovlev V., et al. Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis. BMC Cancer. 2008; 8: 43.
29. Vezina C, Kudelski A, Sehgal SN Rapamycin (AY-22, 989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo). 1975; 28: 721-726.
30. Granville CA, Memmott RM, Gills J.J., et al. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res. 2006; 12(3 PART 1): 679-689.
31. Ng SS, Tsao MS, Nicklee T, et al. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res. 2001; 7: 3269-3275.
32. Ng SS, Tsao MS, Chow S, et al. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res. 2000; 60: 5451-5455.
33. Shah SA, Potter MW, Ricciardi R, et al. FRAP-p70s6K signaling is required for pancreatic cancer cell proliferation. J Surg Res. 2001; 97: 123-130.
34. Yip-Schneider M.T., Wiesenauer CA, Schmidt CM Inhibition of the phosphatidylinositol 30-kinase signaling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac. J Gastro-intest Surg. 2003; 7: 354-363.
35. Bruns CJ, Koehl GE, Guba M, et al. Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin Cancer Res. 2004; 10: 2109-2119.
36. Stephan S, Datta K, Wang E., et al. Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin Cancer Res. 2004; 10: 6993-7000.
37. Stracke S, Ramudo L, Keller F., et al. Antiproliferative and overadditive effects of everolimus and mycophenolate mofetil in pancreas and lung cancer cells in vitro. Transplant Proc. 2006; 38: 766-770.
38. Okada T, Sawada T, Kubota K. Rapamycin enhances the anti-tumor effect of gemcitabine in pancreatic cancer cells. Hepato-gastroenterology. 2007; 54: 2129-2133.
39. Azzariti A, Porcelli L, Gatti G., et al. Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells. Biochem Pharmacol. 2008; 75: 1035-1044.
40. Shen Y, Wang X, Xia W., et al. Antiproliferative and overadditive effects of rapamycin and FTY720 in pancreatic cancer cells in vitro. Transplant Proc. 2008; 40: 1727-1733.
41. Marsh Rde W., Rocha Lima CM, Levy DE, et al. A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am J Clin Oncol. 2007; 30: 26-31.
42. Wolpin BM, Hezel AF, Abrams T, et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2009; 27: 193-198.
43. Li J, Yen C, Liaw D., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997; 275: 1943-1947.
44. Steck PA, Pershouse MA, Jasser S.A., et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997; 15: 356-362.
45. Ebert MP, Fei G, Schandl L., et al. Reduced PTEN expression in the pancreas overexpressing transforming growth factor-beta 1. Br J Cancer. 2002; 86: 257-262.
46. Bellacosa A, Testa JR, Staal S.P., et al. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science. 1991; 254: 274-277.
47. Yamamoto S, Tomita Y, Hoshida Y., et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2004; 10: 2846-2850.
48. Iwenofu OH, Lackman RD, Staddon A.P., et al. Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Mod Pathol. 2008; 21: 231-237.
49. Perez de Obanos MP, Lopez Zabalza MJ, Prieto J, et al. Leucine stimulates procollagen alpha1(I) translation on hepatic stellate cells through ERK and PI3K/Akt/mTOR activation. J Cell Physiol. 2006; 209: 580-586.
50. Zhu J, Wu J, Frizell E., et al. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology. 1999; 117: 1198-1204.
51. Biecker E, De Gottardi A, Neef M, et al. Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms. J Pharmacol Exp Ther. 2005; 313: 952-961.
52. Neef M, Ledermann M, Saegesser H., et al. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol. 2006; 45: 786-796.